BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Hot Electric Vehicles for 2023 - 2Italian police hold suspected boss of Naples Mafia's Mazzarella Clan
- 3Kennedy approves adding two rare disorders to newborn screenings
- 4Poll: Only 25% of Americans think Trump has 'followed through' on his promise to release the Epstein files
- 5Step by step instructions to Pick A Pre-owned vehicle Stage
- Violence 'never part' of break-in plan, court told
- New portrait of the oldest-known supernova | Space photo of the day for March 27, 2026
- Experiences in Natural life Protection: Individual Progressives' Excursions
- Recalled Super Greens diet supplement powder sickens 45 with salmonella
- Pick Your Favored kind of sandwich
- Merz: 80% of Syrians in Germany should return in three years
- Vote In favor of Your Number one Kind Of Food Conveyance Administration
- Man triggers smoke bomb during failed crypto robbery
- Why most Jewish Israelis back the death penalty for terrorists
